Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.
Martin-Broto J, Martinez-Garcia J, Moura DS, Redondo A, Gutierrez A, Lopez-Pousa A, Martinez-Trufero J, Sevilla I, Diaz-Beveridge R, Solis-Hernandez MP, Carnero A, Perez M, Marcilla D, Garcia-Foncillas J, Romero P, Fernandez-Jara J, Lopez-Lopez D, Arribas I, Hindi N.
Martin-Broto J, et al. Among authors: lopez lopez d, lopez pousa a.
Signal Transduct Target Ther. 2023 Oct 25;8(1):405. doi: 10.1038/s41392-023-01661-8.
Signal Transduct Target Ther. 2023.
PMID: 37875500
Free PMC article.
Clinical Trial.